Expansion momentum OMNI International is now integrated within Revvity and actively expanding its software and design capabilities through Signals products. This presents cross-sell opportunities to Revvity’s existing customers and a pathway to introduce enhanced informatics, AI-driven design tools, and standardized data management across biologics workflows.

Biotech startup focus Recent launches like Signals for Startups indicate a strategic emphasis on accelerating early-stage companies’ access to scalable informatics and data management. This creates a sales window to position Revvity’s AI-enabled platforms and designing/bio-design environments to smaller, high-growth biotech firms needing rapid deployment.

Integrated technology stack With a tech stack spanning Illumina, Informatica, TIBCO EBX, Perl and ERP/HR suites, there are opportunities to offer optimized data workflows, integration projects, and customized solutions that connect sequencing, sample prep, and enterprise systems for customers in genomics, proteomics, and biotherapeutics.

Global distribution Partnerships like John Morris Group in Australia/New Zealand and other distributors indicate a ready-made channel strategy. Leverage these partners to expand sales of homogenizers, sample prep solutions, and PhenoVue kits into new regional markets through co-marketing and bundled offerings.

Financial scale Revenue range places OMNI Revvity in mid-market territory with potential for multi-product deals. Target cross-sell of hardware, software licenses, and consumables to larger lab networks and research institutions seeking integrated life sciences workflows and end-to-end solutions.